GOSSAMER BIO INC.
CEO: Sheila Gujrathi
Headquarters: San Diego
Funding: $276 million IPO, preceded by $330 million in two funding rounds
Stock symbol and listing: GOSS on NASDAQ
Company Description: Gossamer has a six-drug pipeline that ranges from oncology to asthma to inflammatory bowel disease.
Two analyst teams who recently started covering Gossamer Bio see a promising future for the San Diego biotech...